fig2
![ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy](https://image.oaes.cc/cbfa8ca1-48a6-4f3c-807e-c3fc79a72622/jcmt100139.fig.2.jpg)
Figure 2. ImmuneScore as a predictor of early disease progression in patients receiving ICI therapy combined with chemotherapy. (A) PD-L1 TPS could not effectively predict early tumor progression; (B) ROC curve and corresponding AUC for PD-L1 TPS in predicting early disease progression; (C) ImmuneScore could predict early tumor progression; (D) ROC curve and corresponding AUC for ImmuneScore in predicting early disease progression. ICI: Immune checkpoint inhibitor; PD-L1 TPS: programmed cell death 1 ligand 1 tumor proportion score; ROC: receiver operating characteristic curve; AUC: area under the ROC curve; PD: progressive disease; PR: partial response; SD: stable disease.